Compare AER & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AER | WAT |
|---|---|---|
| Founded | 1995 | 1958 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.0B | 22.5B |
| IPO Year | 2006 | 1995 |
| Metric | AER | WAT |
|---|---|---|
| Price | $144.25 | $392.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 16 |
| Target Price | $148.86 | ★ $390.67 |
| AVG Volume (30 Days) | ★ 1.0M | 498.3K |
| Earning Date | 02-06-2026 | 02-11-2026 |
| Dividend Yield | ★ 0.75% | N/A |
| EPS Growth | ★ 63.90 | 3.82 |
| EPS | ★ 20.89 | 10.88 |
| Revenue | ★ $8,344,637,000.00 | $3,105,638,000.00 |
| Revenue This Year | $5.14 | $7.96 |
| Revenue Next Year | N/A | $6.32 |
| P/E Ratio | ★ $6.88 | $36.20 |
| Revenue Growth | 6.67 | ★ 6.90 |
| 52 Week Low | $85.57 | $275.05 |
| 52 Week High | $149.24 | $423.56 |
| Indicator | AER | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 55.67 | 56.29 |
| Support Level | $142.28 | $373.54 |
| Resistance Level | $148.59 | $408.67 |
| Average True Range (ATR) | 2.36 | 8.27 |
| MACD | -0.56 | 0.67 |
| Stochastic Oscillator | 28.64 | 58.04 |
AerCap Holdings NV is an aircraft leasing company. Its activities include leasing, financing, sales, and management of commercial aircraft and engines. It also provides aircraft asset management and corporate services to securitization vehicles, joint ventures, and other third parties.It has one business segment: leasing, financing, sales and management of commercial flight equipment (Commercial Flight Equipment Segment).Through its subsidiary, the group also provides engine leasing, certified aircraft engines, airframes, and engine parts. Its geographical segments include United Kingdom, United States, and Other countries.
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.